<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Semaglutide vs Tirzepatide: How to Choose | Moonshot Medical</title>
    <meta name="description" content="Semaglutide (Ozempic/Wegovy) vs Tirzepatide (Mounjaro/Zepbound)—how they work differently, expected results month by month, side effects, muscle loss concerns, and how to decide.">
    <meta name="robots" content="index, follow">
    <link rel="canonical" href="https://moonshotmp.com/learn/semaglutide-vs-tirzepatide/">

    <meta property="og:title" content="Semaglutide vs Tirzepatide: How to Choose">
    <meta property="og:description" content="A detailed comparison of the two leading GLP-1 weight loss medications—mechanism, results, side effects, and how to decide.">
    <meta property="og:url" content="https://moonshotmp.com/learn/semaglutide-vs-tirzepatide/">
    <meta property="og:type" content="article">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:title" content="Semaglutide vs Tirzepatide: How to Choose">
    <meta name="twitter:description" content="A detailed comparison of the two leading GLP-1 weight loss medications—mechanism, results, side effects, and how to decide.">
    <meta property="og:image" content="https://moonshotmp.com/images/scale-weightloss.webp">
    <meta name="twitter:image" content="https://moonshotmp.com/images/scale-weightloss.webp">

    <link rel="icon" href="/favicon.ico" sizes="any">

    <link rel="preload" href="/images/scale-weightloss.webp" as="image">
    <link rel="stylesheet" href="/shared/tailwind.css">
    <link rel="stylesheet" href="/shared/styles.css">

    <script type="application/ld+json">
    {
        "@context": "https://schema.org",
        "@type": "Article",
        "headline": "Semaglutide vs Tirzepatide: How to Choose",
        "description": "A detailed comparison of semaglutide and tirzepatide for weight loss—mechanism, results, side effects, muscle loss, and how to choose between them.",
        "url": "https://moonshotmp.com/learn/semaglutide-vs-tirzepatide/",
        "image": "https://moonshotmp.com/images/scale-weightloss.webp",
        "datePublished": "2025-01-28",
        "dateModified": "2025-01-31",
        "author": {
            "@type": "Person",
            "name": "Moonshot Medical Team",
            "url": "https://moonshotmp.com/about/"
        },
        "publisher": {
            "@type": "Organization",
            "name": "Moonshot Medical and Performance",
            "logo": {
                "@type": "ImageObject",
                "url": "https://moonshotmp.com/images/moonshotmptan.png"
            }
        }
    }
    </script>
    <script type="application/ld+json">
    {
        "@context": "https://schema.org",
        "@type": "FAQPage",
        "mainEntity": [
            {
                "@type": "Question",
                "name": "What is the difference between semaglutide and tirzepatide?",
                "acceptedAnswer": {
                    "@type": "Answer",
                    "text": "Semaglutide (Ozempic/Wegovy) activates GLP-1 receptors only. Tirzepatide (Mounjaro/Zepbound) activates both GLP-1 and GIP receptors—a dual-agonist approach. Both reduce appetite, slow gastric emptying, and improve blood sugar regulation. Tirzepatide's dual mechanism tends to produce slightly more weight loss in clinical trials (20-25% vs 15-20%)."
                }
            },
            {
                "@type": "Question",
                "name": "Which causes more weight loss—semaglutide or tirzepatide?",
                "acceptedAnswer": {
                    "@type": "Answer",
                    "text": "In clinical trials, tirzepatide produced slightly more weight loss on average: 20-25% of body weight vs 15-20% for semaglutide. However, individual results vary significantly. Some patients respond better to one than the other. The best medication is the one that works for your biology with tolerable side effects."
                }
            },
            {
                "@type": "Question",
                "name": "Do GLP-1 medications cause muscle loss?",
                "acceptedAnswer": {
                    "@type": "Answer",
                    "text": "Any rapid weight loss—whether from GLP-1 medications, calorie restriction, or surgery—results in some muscle loss alongside fat loss. Typically 25-40% of weight lost is lean mass. This is not unique to GLP-1s. The key is to mitigate it: strength training, adequate protein intake (0.7-1g per pound of body weight), and monitoring body composition with tools like DEXA scans."
                }
            },
            {
                "@type": "Question",
                "name": "What should I expect month by month on a GLP-1?",
                "acceptedAnswer": {
                    "@type": "Answer",
                    "text": "Month 1-2: Starting dose. Appetite reduction begins, mild GI side effects common, 2-5 lbs lost. Month 3-4: Dose titration. Significant appetite suppression, 8-15 lbs lost total. Month 5-8: Maintenance dose reached. Steady weight loss of 1-2 lbs/week, side effects usually improve. Month 9-12+: Approaching maximum weight loss. Rate slows as body approaches new set point. Total loss typically 15-25% of starting weight."
                }
            },
            {
                "@type": "Question",
                "name": "Can I switch from semaglutide to tirzepatide or vice versa?",
                "acceptedAnswer": {
                    "@type": "Answer",
                    "text": "Yes, switching is possible and sometimes recommended if one medication isn't producing adequate results or is causing intolerable side effects. Your provider will adjust dosing appropriately during the transition. There's no need to restart from scratch."
                }
            }
        ]
    }
    </script>
    <script type="application/ld+json">
    {
        "@context": "https://schema.org",
        "@type": "BreadcrumbList",
        "itemListElement": [
            {"@type": "ListItem", "position": 1, "name": "Home", "item": "https://moonshotmp.com/"},
            {"@type": "ListItem", "position": 2, "name": "Learn", "item": "https://moonshotmp.com/learn/"},
            {"@type": "ListItem", "position": 3, "name": "Semaglutide vs Tirzepatide", "item": "https://moonshotmp.com/learn/semaglutide-vs-tirzepatide/"}
        ]
    }
    </script>
</head>
<body class="font-body selection:bg-brand-gray selection:text-brand-dark flex flex-col min-h-screen">

    <script src="/shared/header.js" defer></script>

    <main class="flex-grow pt-20">

        <!-- Hero -->
        <section class="py-16 bg-brand-dark">
            <div class="max-w-5xl mx-auto px-4 sm:px-6 lg:px-8">
                <a href="/learn/" class="text-brand-gray text-xs uppercase tracking-widest mb-4 hover:text-white inline-block">&larr; Back to Learn</a>
                <div class="grid md:grid-cols-2 gap-12 items-center">
                    <div>
                        <p class="text-brand-gray text-xs uppercase tracking-widest mb-4">Weight Loss</p>
                        <h1 class="text-4xl md:text-5xl font-bold text-brand-light mb-6">SEMAGLUTIDE VS TIRZEPATIDE</h1>
                        <p class="text-brand-gray text-lg font-light">
                            Two medications. Different mechanisms. Both produce significant weight loss. Here's how they compare and how to decide.
                        </p>
                    </div>
                    <div class="aspect-[4/3] bg-brand-slate rounded-sm overflow-hidden">
                        <img src="/images/scale-weightloss.webp" alt="Person stepping on scale during weight loss journey" class="w-full h-full object-cover" width="2000" height="1333" fetchpriority="high">
                    </div>
                </div>
            </div>
        </section>

        <!-- Quick Comparison -->
        <section class="py-12 bg-brand-slate">
            <div class="max-w-4xl mx-auto px-4 sm:px-6 lg:px-8">
                <h2 class="text-2xl font-bold text-brand-light mb-6 text-center">HEAD-TO-HEAD</h2>
                <div class="overflow-x-auto">
                    <table class="w-full text-sm">
                        <thead>
                            <tr class="border-b-2 border-brand-light/30">
                                <th class="text-left py-3 pr-4 text-brand-gray font-light text-xs uppercase tracking-widest"></th>
                                <th class="text-left py-3 px-4 text-brand-light font-bold">Semaglutide</th>
                                <th class="text-left py-3 pl-4 text-brand-light font-bold">Tirzepatide</th>
                            </tr>
                        </thead>
                        <tbody class="text-brand-gray font-light">
                            <tr class="border-b border-white/10">
                                <td class="py-3 pr-4 text-brand-light font-medium text-sm">Brand Names</td>
                                <td class="py-3 px-4">Ozempic, Wegovy, Rybelsus</td>
                                <td class="py-3 pl-4">Mounjaro, Zepbound</td>
                            </tr>
                            <tr class="border-b border-white/10">
                                <td class="py-3 pr-4 text-brand-light font-medium text-sm">Mechanism</td>
                                <td class="py-3 px-4">GLP-1 receptor agonist</td>
                                <td class="py-3 pl-4">GLP-1 + GIP dual agonist</td>
                            </tr>
                            <tr class="border-b border-white/10">
                                <td class="py-3 pr-4 text-brand-light font-medium text-sm">Avg Weight Loss</td>
                                <td class="py-3 px-4">15–20%</td>
                                <td class="py-3 pl-4">20–25%</td>
                            </tr>
                            <tr class="border-b border-white/10">
                                <td class="py-3 pr-4 text-brand-light font-medium text-sm">FDA Approved For</td>
                                <td class="py-3 px-4">Diabetes (Ozempic), Weight loss (Wegovy)</td>
                                <td class="py-3 pl-4">Diabetes (Mounjaro), Weight loss (Zepbound)</td>
                            </tr>
                            <tr class="border-b border-white/10">
                                <td class="py-3 pr-4 text-brand-light font-medium text-sm">Injection Frequency</td>
                                <td class="py-3 px-4">Once weekly</td>
                                <td class="py-3 pl-4">Once weekly</td>
                            </tr>
                            <tr class="border-b border-white/10">
                                <td class="py-3 pr-4 text-brand-light font-medium text-sm">Manufacturer</td>
                                <td class="py-3 px-4">Novo Nordisk</td>
                                <td class="py-3 pl-4">Eli Lilly</td>
                            </tr>
                            <tr>
                                <td class="py-3 pr-4 text-brand-light font-medium text-sm">Available Since</td>
                                <td class="py-3 px-4">2017 (Ozempic)</td>
                                <td class="py-3 pl-4">2022 (Mounjaro)</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </div>
        </section>

        <!-- How They Work -->
        <section class="py-16 bg-brand-light text-brand-dark">
            <div class="max-w-4xl mx-auto px-4 sm:px-6 lg:px-8">
                <h2 class="text-3xl font-bold mb-8">HOW THEY WORK (AND WHY IT MATTERS)</h2>

                <div class="space-y-4 text-brand-slate font-light">
                    <p>
                        Both medications mimic gut hormones that your body produces naturally after eating. The difference is which hormones they mimic.
                    </p>
                </div>

                <div class="mt-8 grid md:grid-cols-2 gap-8">
                    <div class="bg-white border border-brand-slate/10 p-6">
                        <h3 class="font-bold text-xl mb-4">Semaglutide</h3>
                        <p class="text-brand-slate text-xs uppercase tracking-widest mb-4">GLP-1 Agonist</p>
                        <div class="text-brand-slate font-light text-sm space-y-3">
                            <p>
                                Mimics GLP-1 (glucagon-like peptide-1), a hormone released by your gut after eating. GLP-1 does three things:
                            </p>
                            <ul class="space-y-2">
                                <li class="flex items-start gap-2">
                                    <span class="text-brand-dark font-bold">1.</span>
                                    <span><strong class="text-brand-dark">Signals fullness to the brain</strong> — reduces appetite and food noise</span>
                                </li>
                                <li class="flex items-start gap-2">
                                    <span class="text-brand-dark font-bold">2.</span>
                                    <span><strong class="text-brand-dark">Slows gastric emptying</strong> — food stays in your stomach longer, so you feel full longer</span>
                                </li>
                                <li class="flex items-start gap-2">
                                    <span class="text-brand-dark font-bold">3.</span>
                                    <span><strong class="text-brand-dark">Improves insulin sensitivity</strong> — better blood sugar regulation</span>
                                </li>
                            </ul>
                            <p>
                                Semaglutide is a modified version of natural GLP-1 that lasts much longer in the body (natural GLP-1 breaks down in minutes; semaglutide lasts about a week).
                            </p>
                        </div>
                    </div>

                    <div class="bg-white border border-brand-slate/10 p-6">
                        <h3 class="font-bold text-xl mb-4">Tirzepatide</h3>
                        <p class="text-brand-slate text-xs uppercase tracking-widest mb-4">GLP-1 + GIP Dual Agonist</p>
                        <div class="text-brand-slate font-light text-sm space-y-3">
                            <p>
                                Does everything semaglutide does, plus mimics a second hormone: GIP (glucose-dependent insulinotropic polypeptide).
                            </p>
                            <ul class="space-y-2">
                                <li class="flex items-start gap-2">
                                    <span class="text-brand-dark font-bold">+</span>
                                    <span><strong class="text-brand-dark">GIP enhances insulin secretion</strong> — additional blood sugar control</span>
                                </li>
                                <li class="flex items-start gap-2">
                                    <span class="text-brand-dark font-bold">+</span>
                                    <span><strong class="text-brand-dark">GIP affects fat metabolism</strong> — may promote fat burning and reduce fat storage</span>
                                </li>
                                <li class="flex items-start gap-2">
                                    <span class="text-brand-dark font-bold">+</span>
                                    <span><strong class="text-brand-dark">Potentially more satiety signaling</strong> — two pathways instead of one</span>
                                </li>
                            </ul>
                            <p>
                                Think of it as a two-key approach. Semaglutide turns one lock. Tirzepatide turns two. Both open the door, but the dual mechanism may produce a stronger overall effect.
                            </p>
                        </div>
                    </div>
                </div>

                <div class="mt-8 bg-brand-dark text-brand-light p-6">
                    <p class="text-sm font-light">
                        <strong class="text-brand-light">What this means practically:</strong> Tirzepatide tends to produce more weight loss in clinical trials. But biology is individual—some people respond better to one mechanism than the other. "Better on average" doesn't mean "better for you."
                    </p>
                </div>
            </div>
        </section>

        <!-- Clinical Trial Data -->
        <section class="py-16 bg-brand-dark">
            <div class="max-w-4xl mx-auto px-4 sm:px-6 lg:px-8">
                <h2 class="text-3xl font-bold text-brand-light mb-8">WHAT THE CLINICAL TRIALS SHOW</h2>

                <div class="space-y-8">
                    <div class="bg-white/5 border border-white/10 p-6">
                        <h3 class="font-bold text-brand-light mb-2">Semaglutide — STEP Trials</h3>
                        <p class="text-brand-gray text-sm font-light mb-4">The STEP (Semaglutide Treatment Effect in People with Obesity) program enrolled over 4,500 participants across multiple trials.</p>
                        <div class="grid md:grid-cols-3 gap-4 text-center">
                            <div class="bg-brand-dark p-4">
                                <p class="text-2xl font-bold text-brand-light">-14.9%</p>
                                <p class="text-brand-gray text-xs">Avg body weight loss (STEP 1)</p>
                            </div>
                            <div class="bg-brand-dark p-4">
                                <p class="text-2xl font-bold text-brand-light">83%</p>
                                <p class="text-brand-gray text-xs">Lost at least 5% body weight</p>
                            </div>
                            <div class="bg-brand-dark p-4">
                                <p class="text-2xl font-bold text-brand-light">68 weeks</p>
                                <p class="text-brand-gray text-xs">Trial duration</p>
                            </div>
                        </div>
                    </div>

                    <div class="bg-white/5 border border-white/10 p-6">
                        <h3 class="font-bold text-brand-light mb-2">Tirzepatide — SURMOUNT Trials</h3>
                        <p class="text-brand-gray text-sm font-light mb-4">The SURMOUNT program studied tirzepatide for weight management in over 5,000 participants.</p>
                        <div class="grid md:grid-cols-3 gap-4 text-center">
                            <div class="bg-brand-dark p-4">
                                <p class="text-2xl font-bold text-brand-light">-22.5%</p>
                                <p class="text-brand-gray text-xs">Avg body weight loss at highest dose (SURMOUNT-1)</p>
                            </div>
                            <div class="bg-brand-dark p-4">
                                <p class="text-2xl font-bold text-brand-light">96%</p>
                                <p class="text-brand-gray text-xs">Lost at least 5% body weight</p>
                            </div>
                            <div class="bg-brand-dark p-4">
                                <p class="text-2xl font-bold text-brand-light">72 weeks</p>
                                <p class="text-brand-gray text-xs">Trial duration</p>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="mt-8 bg-brand-slate p-6">
                    <p class="text-brand-light text-sm font-light">
                        <strong class="text-brand-light">Context:</strong> Clinical trial participants also received lifestyle intervention (diet and exercise counseling). Real-world results may differ. These numbers represent averages—some people lose more, some lose less. The data shows tirzepatide has an edge at the highest doses, but both produce clinically meaningful weight loss far beyond what lifestyle alone typically achieves.
                    </p>
                </div>
            </div>
        </section>

        <!-- Month by Month -->
        <section class="py-16 bg-brand-light text-brand-dark">
            <div class="max-w-4xl mx-auto px-4 sm:px-6 lg:px-8">
                <h2 class="text-3xl font-bold mb-4 text-center">WHAT TO EXPECT: MONTH BY MONTH</h2>
                <p class="text-brand-slate font-light text-center mb-12 max-w-2xl mx-auto">
                    Both medications follow a similar timeline. You start at a low dose and titrate up over several months to reach your target dose. Here's the general trajectory.
                </p>

                <div class="space-y-6">
                    <div class="grid md:grid-cols-[120px_1fr] gap-4 items-start">
                        <div class="bg-brand-dark text-brand-light p-4 text-center">
                            <p class="text-xs uppercase tracking-widest">Month</p>
                            <p class="text-2xl font-bold">1–2</p>
                        </div>
                        <div class="bg-white border border-brand-slate/10 p-6">
                            <h3 class="font-bold mb-2">Starting Dose — Adjustment Phase</h3>
                            <p class="text-brand-slate text-sm font-light">
                                You'll start at the lowest dose. Appetite reduction begins—many people notice less "food noise" (constant thinking about food) within the first week or two. GI side effects are most common during this phase: nausea, mild stomach discomfort, sometimes constipation. These typically improve as your body adjusts. Weight loss: 2–5 lbs.
                            </p>
                        </div>
                    </div>

                    <div class="grid md:grid-cols-[120px_1fr] gap-4 items-start">
                        <div class="bg-brand-dark text-brand-light p-4 text-center">
                            <p class="text-xs uppercase tracking-widest">Month</p>
                            <p class="text-2xl font-bold">3–4</p>
                        </div>
                        <div class="bg-white border border-brand-slate/10 p-6">
                            <h3 class="font-bold mb-2">Dose Titration — Momentum Builds</h3>
                            <p class="text-brand-slate text-sm font-light">
                                Dose increases to the next level. Appetite suppression is more consistent and pronounced. Most people find portion sizes drop naturally—you just don't want as much food. Side effects typically improve or become manageable. Weight loss accelerates: 8–15 lbs total. This is when most people start noticing visible changes.
                            </p>
                        </div>
                    </div>

                    <div class="grid md:grid-cols-[120px_1fr] gap-4 items-start">
                        <div class="bg-brand-dark text-brand-light p-4 text-center">
                            <p class="text-xs uppercase tracking-widest">Month</p>
                            <p class="text-2xl font-bold">5–8</p>
                        </div>
                        <div class="bg-white border border-brand-slate/10 p-6">
                            <h3 class="font-bold mb-2">Target Dose — Steady State</h3>
                            <p class="text-brand-slate text-sm font-light">
                                You've reached (or are approaching) your target dose. Weight loss is steady—typically 1–2 lbs per week. Energy levels often improve as weight decreases. Metabolic markers start improving: blood sugar, triglycerides, blood pressure. This is the productive middle phase. Total loss: 20–40 lbs depending on starting weight.
                            </p>
                        </div>
                    </div>

                    <div class="grid md:grid-cols-[120px_1fr] gap-4 items-start">
                        <div class="bg-brand-dark text-brand-light p-4 text-center">
                            <p class="text-xs uppercase tracking-widest">Month</p>
                            <p class="text-2xl font-bold">9–12+</p>
                        </div>
                        <div class="bg-white border border-brand-slate/10 p-6">
                            <h3 class="font-bold mb-2">Approaching Maximum — Plateau Management</h3>
                            <p class="text-brand-slate text-sm font-light">
                                Weight loss rate slows as your body approaches a new equilibrium. This is normal—it's not the medication "stopping working." Your body adapts to its new weight. Focus shifts to maintenance, habit consolidation, and body composition optimization. Total loss typically reaches 15–25% of starting body weight.
                            </p>
                        </div>
                    </div>
                </div>

                <div class="mt-8 bg-brand-dark text-brand-light p-6">
                    <p class="text-sm font-light">
                        <strong class="text-brand-light">Individual variation is real.</strong> Some people respond rapidly at lower doses. Others need the full titration to see significant results. Some respond well to semaglutide but not tirzepatide, or vice versa. This is why medical oversight matters—adjusting dose, timing, and even switching medications when needed.
                    </p>
                </div>
            </div>
        </section>

        <!-- Side Effects -->
        <section class="py-16 bg-brand-slate">
            <div class="max-w-4xl mx-auto px-4 sm:px-6 lg:px-8">
                <h2 class="text-3xl font-bold text-brand-light mb-8">SIDE EFFECTS COMPARED</h2>

                <div class="space-y-4 text-brand-gray font-light">
                    <p>
                        Both medications share similar side effect profiles because they work on the same pathways. The most common side effects are gastrointestinal.
                    </p>
                </div>

                <div class="mt-8 grid md:grid-cols-2 gap-8">
                    <div>
                        <h3 class="font-bold text-brand-light mb-4">Common (Both Medications)</h3>
                        <div class="space-y-3">
                            <div class="bg-brand-dark p-4">
                                <p class="text-brand-light font-bold text-sm">Nausea</p>
                                <p class="text-brand-gray text-xs font-light">Most common side effect. Usually worst during dose increases. Typically improves within 2-4 weeks at each dose level.</p>
                            </div>
                            <div class="bg-brand-dark p-4">
                                <p class="text-brand-light font-bold text-sm">Constipation or Diarrhea</p>
                                <p class="text-brand-gray text-xs font-light">GI motility changes affect bowel habits. Often manageable with hydration and fiber.</p>
                            </div>
                            <div class="bg-brand-dark p-4">
                                <p class="text-brand-light font-bold text-sm">Reduced Appetite</p>
                                <p class="text-brand-gray text-xs font-light">This is the intended effect, but some people experience it more intensely—feeling no desire to eat at all. You still need to eat adequate protein.</p>
                            </div>
                            <div class="bg-brand-dark p-4">
                                <p class="text-brand-light font-bold text-sm">Injection Site Reactions</p>
                                <p class="text-brand-gray text-xs font-light">Mild redness or discomfort at injection site. Usually minor.</p>
                            </div>
                        </div>
                    </div>

                    <div>
                        <h3 class="font-bold text-brand-light mb-4">Less Common but Notable</h3>
                        <div class="space-y-3">
                            <div class="bg-brand-dark p-4">
                                <p class="text-brand-light font-bold text-sm">Fatigue</p>
                                <p class="text-brand-gray text-xs font-light">Some people experience tiredness, especially early on. Often related to reduced caloric intake rather than the medication itself.</p>
                            </div>
                            <div class="bg-brand-dark p-4">
                                <p class="text-brand-light font-bold text-sm">Headache</p>
                                <p class="text-brand-gray text-xs font-light">May occur during dose titration. Usually temporary.</p>
                            </div>
                            <div class="bg-brand-dark p-4">
                                <p class="text-brand-light font-bold text-sm">Gallbladder Issues</p>
                                <p class="text-brand-gray text-xs font-light">Rapid weight loss (from any cause) increases gallstone risk. Uncommon but worth monitoring.</p>
                            </div>
                            <div class="bg-brand-dark p-4">
                                <p class="text-brand-light font-bold text-sm">Pancreatitis</p>
                                <p class="text-brand-gray text-xs font-light">Rare but serious. Symptoms include severe abdominal pain radiating to the back. Seek medical attention immediately.</p>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="mt-8 bg-brand-dark p-6">
                    <p class="text-brand-gray text-sm font-light">
                        <strong class="text-brand-light">Key difference:</strong> Side effect rates are roughly comparable between semaglutide and tirzepatide in clinical trials. Some patients tolerate one better than the other—this is individual. If side effects are intolerable on one, switching to the other is a reasonable option.
                    </p>
                </div>
            </div>
        </section>

        <!-- Muscle Loss Section -->
        <section class="py-16 bg-brand-dark">
            <div class="max-w-4xl mx-auto px-4 sm:px-6 lg:px-8">
                <h2 class="text-3xl font-bold text-brand-light mb-8">THE MUSCLE LOSS QUESTION</h2>

                <div class="space-y-4 text-brand-gray font-light">
                    <p>
                        This is the biggest concern people have about GLP-1 medications, and it deserves a straight answer.
                    </p>
                    <p>
                        Yes, you will lose some muscle mass on GLP-1 medications. But context matters: you lose muscle mass with any method of rapid weight loss. Calorie restriction, bariatric surgery, GLP-1s—all of them result in some lean mass loss alongside fat loss. This isn't unique to GLP-1 medications.
                    </p>
                </div>

                <div class="mt-8 bg-white/5 border border-white/10 p-6">
                    <h3 class="font-bold text-brand-light mb-4">The Numbers</h3>
                    <div class="text-brand-gray text-sm font-light space-y-2">
                        <p>In clinical trials, approximately 25-40% of total weight lost on GLP-1 medications was lean mass (muscle + other non-fat tissue). The rest was fat.</p>
                        <p>For comparison:</p>
                        <ul class="space-y-1 mt-2">
                            <li>• Calorie-restricted dieting: ~25-30% lean mass loss</li>
                            <li>• Bariatric surgery: ~25-35% lean mass loss</li>
                            <li>• GLP-1 medications: ~25-40% lean mass loss</li>
                        </ul>
                        <p class="mt-2">The ranges overlap significantly. GLP-1s may be slightly higher because the weight loss is more rapid and dramatic.</p>
                    </div>
                </div>

                <div class="mt-8">
                    <h3 class="font-bold text-brand-light mb-6">How to Minimize Muscle Loss</h3>
                    <div class="grid md:grid-cols-2 gap-6">
                        <div class="bg-white/5 border border-white/10 p-6">
                            <h4 class="font-bold text-brand-light mb-2">Strength Training</h4>
                            <p class="text-brand-gray text-sm font-light">
                                This is the single most important factor. Resistance training 2-4x per week sends a "keep this muscle" signal to your body even while losing weight. The stimulus tells your body to preferentially burn fat instead.
                            </p>
                        </div>
                        <div class="bg-white/5 border border-white/10 p-6">
                            <h4 class="font-bold text-brand-light mb-2">High Protein Intake</h4>
                            <p class="text-brand-gray text-sm font-light">
                                Aim for 0.7–1.0 grams of protein per pound of body weight daily. This is harder on GLP-1s because your appetite is suppressed—you need to prioritize protein even when you don't feel like eating. Protein is the building material your muscles need to survive a calorie deficit.
                            </p>
                        </div>
                        <div class="bg-white/5 border border-white/10 p-6">
                            <h4 class="font-bold text-brand-light mb-2">Track Body Composition</h4>
                            <p class="text-brand-gray text-sm font-light">
                                The scale doesn't tell you what you're losing. A DEXA scan shows exactly how much is fat vs lean mass. If lean mass is dropping too fast, your protocol needs adjusting—more protein, more training, or a slower rate of loss.
                            </p>
                        </div>
                        <div class="bg-white/5 border border-white/10 p-6">
                            <h4 class="font-bold text-brand-light mb-2">Don't Undershoot Calories</h4>
                            <p class="text-brand-gray text-sm font-light">
                                GLP-1s can suppress appetite so aggressively that some people barely eat. Extreme caloric restriction accelerates muscle loss. You should still eat—aim for a moderate deficit with adequate protein, not starvation-level intake.
                            </p>
                        </div>
                    </div>
                </div>

                <div class="mt-8 bg-brand-slate p-6">
                    <p class="text-brand-light text-sm font-light">
                        <strong class="text-brand-light">Our approach:</strong> Every weight loss patient at Moonshot gets baseline DEXA scanning to track body composition over time. We're not just watching the number on the scale go down—we're monitoring what kind of weight you're losing. If muscle loss is excessive, we adjust the plan.
                    </p>
                </div>
            </div>
        </section>

        <!-- What Happens When You Stop -->
        <section class="py-16 bg-brand-light text-brand-dark">
            <div class="max-w-4xl mx-auto px-4 sm:px-6 lg:px-8">
                <h2 class="text-3xl font-bold mb-8">WHAT HAPPENS WHEN YOU STOP?</h2>

                <div class="space-y-4 text-brand-slate font-light">
                    <p>
                        This is the question everyone should ask before starting. The honest answer: most people regain a significant portion of the weight after stopping GLP-1 medications.
                    </p>
                    <p>
                        The STEP 1 trial extension showed that participants who stopped semaglutide regained about two-thirds of the weight they lost within one year. Tirzepatide data shows a similar pattern.
                    </p>
                    <p>
                        This isn't a failure of willpower. It's biology. These medications work by overriding your body's weight defense mechanisms—hunger hormones, metabolic adaptation, appetite signaling. When you stop the medication, those mechanisms return to their baseline settings.
                    </p>
                </div>

                <div class="mt-8 bg-brand-dark text-brand-light p-6">
                    <h3 class="font-bold mb-3">What This Means for Your Plan</h3>
                    <div class="text-brand-gray text-sm font-light space-y-3">
                        <p><strong class="text-brand-light">Option 1: Long-term use.</strong> Some patients stay on GLP-1 medications long-term at maintenance doses. This is increasingly recognized as a valid approach for obesity management, similar to how blood pressure or cholesterol medications are used long-term.</p>
                        <p><strong class="text-brand-light">Option 2: Use as a bridge.</strong> Use the medication to lose weight while building exercise and nutrition habits. Taper off gradually and rely on lifestyle changes. Some weight regain is likely but not all—especially if you've maintained muscle and built real habits.</p>
                        <p><strong class="text-brand-light">Option 3: Cycle on and off.</strong> Use the medication in defined periods, maintain with lifestyle between cycles. Less studied but commonly practiced.</p>
                    </div>
                </div>
            </div>
        </section>

        <!-- How to Choose -->
        <section class="py-16 bg-brand-slate">
            <div class="max-w-4xl mx-auto px-4 sm:px-6 lg:px-8">
                <h2 class="text-3xl font-bold text-brand-light mb-8 text-center">HOW TO CHOOSE</h2>

                <div class="space-y-6">
                    <div class="bg-brand-dark p-6">
                        <h3 class="font-bold text-brand-light mb-2">Semaglutide might be a better fit if:</h3>
                        <ul class="text-brand-gray text-sm font-light space-y-2">
                            <li>• You want the medication with the longest track record (available since 2017)</li>
                            <li>• Your insurance covers it (semaglutide has broader insurance coverage currently)</li>
                            <li>• You've tried tirzepatide and experienced intolerable side effects</li>
                            <li>• You prefer an oral option (Rybelsus is available as a daily pill, though the injectable form is more effective for weight loss)</li>
                        </ul>
                    </div>
                    <div class="bg-brand-dark p-6">
                        <h3 class="font-bold text-brand-light mb-2">Tirzepatide might be a better fit if:</h3>
                        <ul class="text-brand-gray text-sm font-light space-y-2">
                            <li>• You want the highest average weight loss based on clinical data</li>
                            <li>• You have significant insulin resistance or type 2 diabetes (the dual mechanism may provide better blood sugar control)</li>
                            <li>• Semaglutide wasn't effective enough at maximum dose</li>
                            <li>• You want to maximize results and the cost difference isn't a barrier</li>
                        </ul>
                    </div>
                    <div class="bg-brand-dark p-6">
                        <h3 class="font-bold text-brand-light mb-2">The truth:</h3>
                        <p class="text-brand-gray text-sm font-light">
                            Both work well. For most people, the deciding factors end up being availability, cost/insurance coverage, and individual side effect tolerance. If one doesn't work optimally, you can switch to the other. This isn't a permanent decision.
                        </p>
                    </div>
                </div>
            </div>
        </section>

        <!-- FAQ -->
        <section class="py-16 bg-brand-light text-brand-dark">
            <div class="max-w-4xl mx-auto px-4 sm:px-6 lg:px-8">
                <h2 class="text-3xl font-bold mb-12 text-center">COMMON QUESTIONS</h2>

                <div class="space-y-6">
                    <div class="bg-white border border-brand-slate/10 p-6">
                        <h3 class="font-bold mb-2">Can I take a GLP-1 if I'm not obese?</h3>
                        <p class="text-brand-slate font-light text-sm">
                            FDA approval is for BMI 30+ (or 27+ with weight-related conditions). However, off-label use for lower BMIs is possible when there's a clinical rationale. This is a conversation for your provider based on your specific health picture.
                        </p>
                    </div>
                    <div class="bg-white border border-brand-slate/10 p-6">
                        <h3 class="font-bold mb-2">Will I need to inject myself?</h3>
                        <p class="text-brand-slate font-light text-sm">
                            Yes. Both are weekly subcutaneous injections using a pre-filled pen—similar to insulin pens. The needle is very small and the injection is just under the skin (not into muscle). Most patients are comfortable with self-injection after the first time.
                        </p>
                    </div>
                    <div class="bg-white border border-brand-slate/10 p-6">
                        <h3 class="font-bold mb-2">Can I drink alcohol on GLP-1 medications?</h3>
                        <p class="text-brand-slate font-light text-sm">
                            There's no strict prohibition, but many patients report lower alcohol tolerance and increased nausea with alcohol. GLP-1s slow gastric emptying, so alcohol absorption patterns may change. Many patients naturally drink less because they just don't want it. Excessive alcohol should be avoided as it adds empty calories and can worsen GI side effects.
                        </p>
                    </div>
                    <div class="bg-white border border-brand-slate/10 p-6">
                        <h3 class="font-bold mb-2">How much does it cost at Moonshot?</h3>
                        <p class="text-brand-slate font-light text-sm">
                            Our full Weight Loss program is $405/month (includes medication, medical oversight, labs, DEXA tracking, and dose management). If your insurance covers the GLP-1 medication, we offer a Prescription Program at $105/month for oversight and monitoring.
                        </p>
                    </div>
                </div>
            </div>
        </section>

        <!-- References -->
        <section class="py-12 bg-brand-dark">
            <div class="max-w-4xl mx-auto px-4 sm:px-6 lg:px-8">
                <h3 class="font-bold text-sm uppercase tracking-widest text-brand-light mb-4">References</h3>
                <ul class="text-brand-gray text-xs font-light space-y-2">
                    <li>1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021;384(11):989-1002. (STEP 1)</li>
                    <li>2. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022;387(3):205-216. (SURMOUNT-1)</li>
                    <li>3. Wilding JPH, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide." Diabetes Obes Metab. 2022;24(8):1553-1564. (STEP 1 Extension)</li>
                    <li>4. Aronne LJ, et al. "Continued treatment with tirzepatide for maintenance of weight reduction." JAMA. 2024;331(1):38-48. (SURMOUNT-4)</li>
                    <li>5. Heymsfield SB, et al. "Mechanisms, Pathophysiology, and Management of Obesity." N Engl J Med. 2017;376(3):254-266.</li>
                    <li>6. Mechanick JI, et al. "Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures." Obesity. 2020;28(4):O1-O58.</li>
                </ul>
            </div>
        </section>

        <!-- Related -->
        <section class="py-12 bg-brand-slate">
            <div class="max-w-4xl mx-auto px-4 sm:px-6 lg:px-8">
                <p class="text-brand-gray text-sm uppercase tracking-widest mb-4">Related Reading</p>
                <div class="flex flex-wrap gap-4">
                    <a href="/medical/glp1-vs-other-weight-loss/" class="bg-brand-dark px-6 py-3 text-brand-light text-sm hover:bg-white/10 transition">GLP-1 vs Other Weight Loss Methods &rarr;</a>
                    <a href="/medical/weight-loss/" class="bg-brand-dark px-6 py-3 text-brand-light text-sm hover:bg-white/10 transition">Weight Loss Services at Moonshot &rarr;</a>
                    <a href="/learn/optimal-vs-normal/" class="bg-brand-dark px-6 py-3 text-brand-light text-sm hover:bg-white/10 transition">Optimal vs Normal Lab Ranges &rarr;</a>
                </div>
            </div>
        </section>

        <!-- CTA -->
        <section class="py-20 bg-brand-dark text-center">
            <div class="max-w-4xl mx-auto px-4 sm:px-6 lg:px-8">
                <h2 class="text-4xl font-bold text-brand-light mb-6">READY TO START?</h2>
                <p class="text-xl text-brand-gray font-light mb-10">
                    We'll evaluate your health history, discuss which medication makes sense for you, and build a plan that protects muscle while you lose fat.
                </p>
                <a href="/booking/" class="btn-primary text-lg px-8 py-4">Book Consultation</a>
            </div>
        </section>

    </main>

    <script src="/shared/footer.js"></script>

</body>
</html>
